Importance of haplotype analysis in association studies considering VEGF promoter polymorphisms

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 747-

  Luizon, Marcelo Rizzatti ^a   Sandrim, Valeria Cristina ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Programa de Pos Graduacao e Pesquisa   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMYOTROPHIC LATERAL SCLEROSIS; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MIGRAINE; PREECLAMPSIA; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; HUMANS; HYPERTENSION; MALE; MICROVESSELS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955811234     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.02.015     Document Type: Letter

References (10)

1. Palmirotta R., Ferroni P., Ludovici G., Martini F., Savonarola A., D'Alessandro R., et al. Vegf-a gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clinical Biochemistry 2010, 43:1090-1095.
2. Crawford D.C., Nickerson D.A. Definition and clinical importance of haplotypes. Annual Review of Medicine 2005, 56:303-320.
3. Sandrim V.C., Palei A.C., Cavalli R.C., Araujo F.M., Ramos E.S., Duarte G., et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Molecular Human Reproduction 2009, 15:115-120.
4. Goncalves F.M., Martins-Oliveira A., Speciali J.G., Izidoro-Toledo T.C., Luizon M.R., Dach F., et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in women with migraine. DNA and Cell Biology 2010, 29:357-362.
5. Demacq C., Vasconcellos V.B., Izidoro-Toledo T.C., da Silva Silveira V., Canalle R., Queiroz R.G., et al. Vascular endothelial growth factor (vegf) and endothelial nitric oxide synthase (nos3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (all). Clinica Chimica Acta; International Journal of Clinical Chemistry 2010, 411:1335-1340.
6. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., et al. Vegf is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genetics 2003, 34:383-394.
7. Sandrim V.C., Tanus-Santos J.E. Haplotype analysis can provide improved clinical information than single genotype analysis. Thrombosis Research 2007, 120:779.
8. Prior S.J., Hagberg J.M., Paton C.M., Douglass L.W., Brown M.D., McLenithan J.C., et al. DNA sequence variation in the promoter region of the vegf gene impacts vegf gene expression and maximal oxygen consumption. The American Journal of Physiology 2006, 290:H1848-H1855.
9. Stevens A., Soden J., Brenchley P.E., Ralph S., Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Research 2003, 63:812-816.
10. Muniz J.J., Izidoro-Toledo T.C., Metzger I.F., Sandrim V.C., Tanus-Santos J.E. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA and Cell Biology 2009, 28:567-572.